Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia.

PubWeight™: 1.33‹?› | Rank: Top 10%

🔗 View Article (PMID 12852712)

Published in Clin Ther on March 01, 2003

Authors

Richard G Wunderink1, Sue K Cammarata, Thomas H Oliphant, Marin H Kollef, Linezolid Nosocomial Pneumonia Study Group

Author Affiliations

1: Methodist Healthcare Memphis and the University of Tennessee, Memphis, Tennessee 38104-3499, USA. WunderiR@methodisthealth.org

Articles citing this

Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol (2009) 10.42

Community-associated meticillin-resistant Staphylococcus aureus. Lancet (2010) 9.07

Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev (2015) 1.94

Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest (2010) 1.76

Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol (2008) 1.68

Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med (2010) 1.43

LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrob Agents Chemother (2011) 1.25

Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother (2006) 1.13

Linezolid surveillance results for the United States: LEADER surveillance program 2011. Antimicrob Agents Chemother (2012) 1.05

Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med (2008) 1.03

Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open (2013) 0.99

Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy. Eur J Med Res (2010) 0.94

Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. Crit Care (2014) 0.90

Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. Eur J Clin Pharmacol (2014) 0.87

Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia. Clin Infect Dis (2010) 0.83

The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections. PLoS One (2013) 0.83

Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol (2016) 0.83

Update on the appropriate use of linezolid in clinical practice. Ther Clin Risk Manag (2006) 0.82

Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis (2013) 0.81

Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. Mayo Clin Proc (2012) 0.79

Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion. J Inflamm (Lond) (2010) 0.75

Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People's Republic of China. Clinicoecon Outcomes Res (2016) 0.75

Year in review 2012: Critical Care--respiratory infections. Crit Care (2013) 0.75

Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. Br J Clin Pharmacol (2017) 0.75

Articles by these authors

Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis (2012) 7.97

Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest (2002) 6.13

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 5.64

Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother (2005) 5.35

Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest (2006) 4.51

Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med (2006) 4.10

Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest (2002) 3.98

Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis (2008) 3.88

Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis (2011) 3.78

The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs (2007) 3.63

Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother (2005) 3.49

Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis (2011) 3.20

Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis (2008) 3.13

Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA (2012) 3.13

The importance of fluid management in acute lung injury secondary to septic shock. Chest (2009) 2.92

Impact of Sepsis Classification and Multidrug-Resistance Status on Outcome Among Patients Treated With Appropriate Therapy. Crit Care Med (2015) 2.87

Time to Appropriate Antibiotic Therapy Is an Independent Determinant of Postinfection ICU and Hospital Lengths of Stay in Patients With Sepsis. Crit Care Med (2015) 2.86

Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med (2005) 2.70

Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med (2003) 2.59

Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest (2008) 2.57

Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis. Crit Care Med (2009) 2.57

Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database. Crit Care Med (2006) 2.51

Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother (2007) 2.49

Implementation of a real-time computerized sepsis alert in nonintensive care unit patients. Crit Care Med (2011) 2.35

Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest (2013) 2.32

Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med (2004) 2.30

A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest (2004) 2.26

Endotracheal tube intraluminal volume loss among mechanically ventilated patients. Crit Care Med (2004) 2.20

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis (2001) 2.19

Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med (2011) 2.16

Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial. JPEN J Parenter Enteral Nutr (2002) 2.15

Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med (2010) 2.15

Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol (2004) 2.13

Association between a silver-coated endotracheal tube and reduced mortality in patients with ventilator-associated pneumonia. Chest (2009) 2.09

Pneumonia Pathogen Characterization Is an Independent Determinant of Hospital Readmission. Chest (2015) 2.09

Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med (2008) 2.06

A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther (2007) 2.05

Attitudes of respiratory therapists and nurses about measures to prevent ventilator-associated pneumonia: a multicenter, cross-sectional survey study. Respir Care (2007) 2.03

Delirium as detected by the CAM-ICU predicts restraint use among mechanically ventilated medical patients. Crit Care Med (2005) 1.92

Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs? Crit Care Med (2007) 1.88

Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment. Crit Care Med (2006) 1.86

A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria. Crit Care Med (2012) 1.82

Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in BAL fluid of patients with pulmonary infiltrates in the ICU. Chest (2008) 1.81

Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med (2006) 1.80

Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia. Crit Care Med (2002) 1.72

Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implications. Crit Care Med (2008) 1.72

Antimicrobial stewardship in the intensive care unit: advances and obstacles. Am J Respir Crit Care Med (2009) 1.71

Silver-coated endotracheal tubes associated with reduced bacterial burden in the lungs of mechanically ventilated dogs. Chest (2002) 1.63

Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care (2012) 1.62

Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol (2007) 1.61

Nursing adherence with evidence-based guidelines for preventing ventilator-associated pneumonia. Crit Care Med (2003) 1.61

Identifying critically ill patients at risk for inappropriate antibiotic therapy: a pilot study of a point-of-care decision support alert. Crit Care Med (2014) 1.60

Readmission following hospitalization for pneumonia: the impact of pneumonia type and its implication for hospitals. Clin Infect Dis (2013) 1.60

A prospective evaluation of ventilator-associated conditions and infection-related ventilator-associated conditions. Chest (2015) 1.59

Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med (2008) 1.58

Tracheobronchial aspiration of gastric contents in critically ill tube-fed patients: frequency, outcomes, and risk factors. Crit Care Med (2006) 1.57

Use of a handheld computer by respiratory care practitioners to improve the efficiency of weaning patients from mechanical ventilation. Crit Care Med (2002) 1.56

The modified APACHE II score outperforms Curb65 pneumonia severity score as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chest (2007) 1.53

A randomized trial of conventional chest physical therapy versus high frequency chest wall compressions in intubated and non-intubated adults. Respir Care (2011) 1.51

Patient safety event reporting in critical care: a study of three intensive care units. Crit Care Med (2007) 1.51

Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med (2004) 1.49

Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest (2008) 1.47

Non-invasive stroke volume measurement and passive leg raising predict volume responsiveness in medical ICU patients: an observational cohort study. Crit Care (2009) 1.47

Epidemiology and outcomes of clostridium difficile-associated disease among patients on prolonged acute mechanical ventilation. Chest (2009) 1.47

Physicians' estimates of cardiac index and intravascular volume based on clinical assessment versus transesophageal Doppler measurements obtained by critical care nurses. Am J Crit Care (2003) 1.46

Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest (2004) 1.45

Diagnostic utility of plasma procalcitonin for nosocomial pneumonia in the intensive care unit setting. Respir Care (2011) 1.45

Prevention of hospital infection. Microbes Infect (2005) 1.45

Activity of a silver-coated endotracheal tube in preclinical models of ventilator-associated pneumonia and a study after extubation. Crit Care Med (2010) 1.42

Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol (2008) 1.42

Ambulatory care-sensitive conditions: clinical outcomes and impact on intensive care unit resource use. South Med J (2003) 1.42

Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial. Clin Infect Dis (2005) 1.40

Addition of vasopressin to norepinephrine as independent predictor of mortality in patients with refractory septic shock: an observational study. Surg Infect (Larchmt) (2007) 1.39

Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care (2006) 1.37

Staphylococcus aureus nasal colonization and subsequent infection in intensive care unit patients: does methicillin resistance matter? Infect Control Hosp Epidemiol (2010) 1.34

Cost and mortality prediction using polymerase chain reaction pathogen detection in sepsis: evidence from three observational trials. Crit Care (2010) 1.33

Analysis of 30-day mortality for clostridium difficile-associated disease in the ICU setting. Chest (2007) 1.30

Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis (2010) 1.29

Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother (2010) 1.27

Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy (2010) 1.25

Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med (2002) 1.25

The effect of an education program on the incidence of central venous catheter-associated bloodstream infection in a medical ICU. Chest (2004) 1.24

Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000-2005. Pediatr Infect Dis J (2008) 1.20

Transfusion practice and blood stream infections in critically ill patients. Chest (2005) 1.19

Why do physicians not follow evidence-based guidelines for preventing ventilator-associated pneumonia?: a survey based on the opinions of an international panel of intensivists. Chest (2002) 1.18

A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care (2012) 1.18

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother (2003) 1.17

An educational intervention to reduce ventilator-associated pneumonia in an integrated health system: a comparison of effects. Chest (2004) 1.16

Red blood cell transfusion and ventilator-associated pneumonia: A potential link? Crit Care Med (2004) 1.15

Fluid balance and cardiac function in septic shock as predictors of hospital mortality. Crit Care (2013) 1.14

Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis. Crit Care Med (2005) 1.13

Risk factors for ventilator-associated pneumonia: from epidemiology to patient management. Clin Infect Dis (2004) 1.13

Reporting of medical errors: an intensive care unit experience. Crit Care Med (2004) 1.13

Early prediction of septic shock in hospitalized patients. J Hosp Med (2010) 1.12

Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005. Emerg Infect Dis (2008) 1.10

Probiotics for preventing and treating nosocomial infections: review of current evidence and recommendations. Chest (2007) 1.09

Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Crit Care Med (2004) 1.09

A comparison of culture-positive and culture-negative health-care-associated pneumonia. Chest (2009) 1.07

A trial of a real-time alert for clinical deterioration in patients hospitalized on general medical wards. J Hosp Med (2013) 1.06